Literature DB >> 8479498

Treatment of Gaucher's disease.

C E Hollak, J M Aerts, M H van Oers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8479498

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 2.  Current issues in enzyme therapy for Gaucher disease.

Authors:  G A Grabowski
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

3.  The effect of enzyme therapy in a patient with Gaucher disease type III.

Authors:  D K Bosman; C E Hollak; J M Aerts; H D Bakker
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 4.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

5.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.